高频热疗联合吉西他滨治疗老年中晚期非小细胞肺癌临床观察

目的观察高频热疗联合吉西他滨单药化疗治疗老年中晚期非小细胞肺癌的近期疗效、生存率、毒副作用及临床受益情况。方法将2003年2月至2006年12月间共80例老年中晚期非小细胞肺癌患者随机分入观察组和对照组。观察组（40例）采用高频热疗联合吉西他滨单药化疗,共4个周期,治疗结束后1个月评价疗效及毒副作用;对照组（40例）采用吉西他滨联合顺铂化疗,共4个周期,治疗结束后1个月评价疗效及毒副作用。然后对两组患者进行随访,统计生存率并进行比较。结果观察组与对照组比较,近期疗效差异无显著性,临床受益率明显提高,毒副作用减少,1,2年生存率差异无显著性。结论高频热疗联合吉西他滨单药化疗治疗老年中晚期非小细胞肺癌疗效确切,临床受益率明显提高,毒副作用可耐受。

Clinical observation of hyperthermia combined with gemcitabine in the treatment of old patients with advanced non-small cell lung cancer

Objective To observe the clinical efficacy,survival rate,clinical benefit response and side effects induced by gemcitabine plus hyperthermia in the treatment of old patients with advanced non-small cell lung cancer（NSCLC）.Methods A total of 80 old patients with advanced NSCLC were recruited and divided into 40 cases in gemcitabine plus hyperthermia group（group A） and 40 cases in systemic chemotherapy group（group B）.The patients in the group A received gemcitabine for 4 cycles,and at the same time received local hyperthermia therapy for 1 hour twice every three days. The patients in the group B received gemcitabine plus cisplatin regimen for 4 cycles. Then the survival rates of two groups were observed. Results The objective effective rate （OR） was 45.0% in group A and 35.0% in group B. The difference was not significant（χ2 = 0. 8333 , P 〉 0. 05 ）. The clinical benefit response （CBR） was 87. 5% in group A and 67. 5% in group B, with significant difference between the two groups （χ2 = 4. 5878, P 〈 0. 05 ）. The toxic and side effects was less in group A than in group B. Conclusion Hyperthermia combined with gemcitabine is well tolerated and increases the clinical benefit response（CBR） in the treatment of old patients with ad- vance NSCLC.